Impressum Bookmark Kontakt Sitemap
Solide Tumoren - Verdauungstrakt - Magen- und AEG-Karzinome -
Weiterführende Informationen

Magen- und AEG-Karzinome

Leitlinien

 

S3-Leitlinien [27], Volltext online


NCCN guidelines vgl. Volltext online (Registrierung erforderlich)

 

ESMO expert opinion [vgl. 14]

 

Studien

 

www.aio-portal.de, www.clinicaltrials.gov (NIH/USA)

 

Literatur

 

  1. Siewert JR et al: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005; 90: 139–46
  2. Yamashita H et al: Optimal Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junction Carcinoma. Ann Surg. 2011; 254: 274–80
  3. Yonemura Y et al: Metastasis in paraaortic lymph node in Pat.s with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology 2007; 54: 634–8
  4. Songun I et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439–49
  5. Patriti A et al: Robot-assisted laparoscopic management of cardia carcinoma according to Siewert recommendations. Int J Med Robot. 2011; 7: 170-7
  6. Strong VE et al: Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol 2009; 16: 1507–13
  7. Stahl M et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851–6
  8. Sjoquist KM et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681–92
  9. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303(17): 1729–37
  10. Fuchs C et al: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29: 2011 (suppl; abstr 4003)
  11. Thuss-Patience PC et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; epub ahead of print. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27: (suppl): 15s, abstr 4540
  12. Park SH et al: A multicenter, randomized phase III trial comparing second-line chemotherapy plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer. J Clin Oncol 29: 2011 (suppl; abstr 4004)
  13. Hartmann JT et al: Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. Onkologie 2007; 30: 235–40
  14. Van Cutsem E et al: The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 Ann Oncol 2011; 22 (suppl 5):v1-9
  15. Van Cutsem E et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27 (suppl): 18s, abstr LBA4509
  16. Cunningham D et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20
  17. Ychou M, et al: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29(13): 1715–21
  18. Kollmannsberger C et al: Adjuvant RCTx using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: 2 cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 2005; 16: 1326–33
  19. Hofheinz RD et al: Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer – an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 2009; 73: 142–7
  20. Lutz M et al: Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25: 2580–5
  21. Kang Y et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666–73
  22. Al-Batran SE: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435–42
  23. Cunningham D et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36–46
  24. Van Cutsem E et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991–7
  25. Al-Batran SE et al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the AIO. Ann Oncol 2008; 19: 1882–7
  26. Dank M et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy-naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450–7
  27. Bang YJ et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–97